At a glance
ClinicalIndex Comparison Record- ✓Insulin resistance
- ✓Triglycerides ≥150 mg/dL or triglyceride-to-HDL-C ratio ≥3
- ✓BMI 25–35 kg/m²
- ✕Diabetes mellitus
- ✕History of gallstones
- ✕History of congestive heart failure (CHF)
- ✕History of coronary artery disease (CAD)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison Fenofibrate, Rosiglitazone, or Weight Loss to Decrease Cardiovascular Risk in Insulin Resistant Dyslipidemic Individuals.
In Brief
A clinical study evaluating Rosiglitazone, Fenofibrate, and 1 other intervention for Insulin Resistance and Hypertriglyceridemia. Completed, enrolled 47 participants across 1 site.
Detailed Summary
Approximately 1/4 of the US population has insulin resistance and the associated risk factors such as elevated lipid levels -triglycerides (type of fat from what we eat and what the liver produces and low HDL cholesterol which is the good cholesterol helping to protect against heart disease. Currently one known treatment for this a medication called fenofibrate, another medication that can improve insulin resistance is rosiglitazone, a third treatment known to improve insulin resistance an decrease triglycerides is weight loss. In this study insulin resistant individuals with elevated triglycerides and or a ratio of triglycerides to HDL cholesterol of 3:1 or greater will be randomized (selected by chance) to receive one of these treatments and results of insulin sensitivity and cardiac risk profiles will be compared at the end of the study.